{"DataElement":{"publicId":"4534247","version":"1","preferredName":"Malignant Neoplasm Residual Mass Pathology Assessment Type","preferredDefinition":"The type related to the pathology of residual masses.","longName":"RMASSPATH","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"4534242","version":"1","preferredName":"Malignant Neoplasm Residual Mass Pathology Assessment","preferredDefinition":"Information related to the pathology of residual masses.","longName":"RMASSPATH","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2186369","version":"1","preferredName":"Malignant Neoplasm","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0647F5B-A888-4B87-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-03","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4534240","version":"1","preferredName":"Residual Mass Pathology Assessment","preferredDefinition":"Remaining or left behind.:A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.:The final result of a determination of the value, significance, or extent of.","longName":"C37895:C34808:C18189:C25217","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Mass","conceptCode":"C34808","definition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathology","conceptCode":"C18189","definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05508BDE-30BD-77D7-E050-BB89AD436029","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ONEDATA","dateModified":"2014-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05508BDE-30CE-77D7-E050-BB89AD436029","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4534244","version":"1","preferredName":"Residual Mass Pathology Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"RMASSPATH","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Viable GCT","valueDescription":"Viable GCT","ValueMeaning":{"publicId":"4534245","version":"1","preferredName":"Viable GCT","longName":"4534245","preferredDefinition":"Viable GCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0550E965-2B60-1996-E050-BB89AD430434","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0550E965-2B79-1996-E050-BB89AD430434","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ONEDATA","dateModified":"2014-10-13","deletedIndicator":"No"},{"value":"Teratoma with malignant transformation","valueDescription":"Teratoma with malignant transformation","ValueMeaning":{"publicId":"2573020","version":"1","preferredName":"Teratoma with malignant transformation","longName":"2573020","preferredDefinition":"Teratoma with malignant transformation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA49-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"MAESKEB","dateModified":"2005-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0550E965-2B83-1996-E050-BB89AD430434","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ONEDATA","dateModified":"2014-10-13","deletedIndicator":"No"},{"value":"Teratoma","valueDescription":"Teratoma","ValueMeaning":{"publicId":"2566025","version":"1","preferredName":"Teratoma","longName":"2566025","preferredDefinition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as mature or immature. Mature teratomas are composed of well differentiated, adult-type tissues. Immature teratomas are composed of immature, fetal-type tissues. Testicular teratomas in children follow a benign clinical course. Mature ovarian teratomas without a fetal-type component have an excellent outcome. The prognosis of immature ovarian teratomas is related to the grade and stage of the tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teratoma","conceptCode":"C3403","definition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as benign (grade 0 or 1), immature (grade 2), and malignant (grade 3). Grade 0 teratomas contain only mature elements; grade 1 teratomas have a limited degree of immaturity; grade 2 teratomas have a more extensive degree of immaturity; grade 3 teratomas are composed exclusively of immature tissues. The prognosis depends on patient age, tumor size and grade, and stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CEF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-05-30","modifiedBy":"COOPERM","dateModified":"2012-11-09","changeDescription":"Added system generated definition for TCGA. mc 11/9/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0550E965-2B8E-1996-E050-BB89AD430434","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ONEDATA","dateModified":"2014-10-13","deletedIndicator":"No"},{"value":"Necrosis or fibrosis or other benign finding only","valueDescription":"Necrosis or fibrosis or other benign finding only","ValueMeaning":{"publicId":"4534246","version":"1","preferredName":"Necrosis or fibrosis or other benign finding only","longName":"4534246","preferredDefinition":"Necrosis or fibrosis or other benign finding only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0550E965-2B99-1996-E050-BB89AD430434","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0550E965-2BB2-1996-E050-BB89AD430434","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ONEDATA","dateModified":"2014-10-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0550E965-2B4C-1996-E050-BB89AD430434","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ZIEGLERK","dateModified":"2014-11-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Pathology of residual masses","type":"Preferred Question Text","description":"Pathology of residual masses","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0550E965-2BC3-1996-E050-BB89AD430434","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-10-13","modifiedBy":"ZIEGLERK","dateModified":"2014-11-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}